Raymond J. Henley Iii

Array ( [id] => 18603391 [patent_doc_number] => 11744831 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-05 [patent_title] => Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections [patent_app_type] => utility [patent_app_number] => 17/362103 [patent_app_country] => US [patent_app_date] => 2021-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 27 [patent_no_of_words] => 40083 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 159 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17362103 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17297776 [patent_doc_number] => 20210393615 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => METHODS FOR TREATING NEUROLOGICAL CONDITIONS AND EXPOSURE TO NERVE AGENTS [patent_app_type] => utility [patent_app_number] => 17/360912 [patent_app_country] => US [patent_app_date] => 2021-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20384 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17360912 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18931019 [patent_doc_number] => 11883413 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-30 [patent_title] => Inhibition of thymine DNA glycosylase in the treatment of cancer [patent_app_type] => utility [patent_app_number] => 17/358852 [patent_app_country] => US [patent_app_date] => 2021-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 46 [patent_no_of_words] => 11725 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17358852 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18443559 [patent_doc_number] => 11679110 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-20 [patent_title] => Methods of treating disorders using CSF1R inhibitors [patent_app_type] => utility [patent_app_number] => 17/358137 [patent_app_country] => US [patent_app_date] => 2021-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 19 [patent_no_of_words] => 122474 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17358137 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17807307 [patent_doc_number] => 20220259142 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-18 [patent_title] => METHODS OF TREATING NEUROFIBROMATOSIS WITH N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)-BENZAMIDE [patent_app_type] => utility [patent_app_number] => 17/357593 [patent_app_country] => US [patent_app_date] => 2021-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15932 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17357593 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18179857 [patent_doc_number] => 20230040586 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/355813 [patent_app_country] => US [patent_app_date] => 2021-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 73069 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17355813 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17154837 [patent_doc_number] => 20210315888 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => METHOD OF PROVIDING ARIPIPRAZOLE TO PATIENTS HAVING IMPAIRED CYP2D6 OR CYP3A4 ENZYME FUNCTION [patent_app_type] => utility [patent_app_number] => 17/304610 [patent_app_country] => US [patent_app_date] => 2021-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4333 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17304610 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17140086 [patent_doc_number] => 20210308097 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => WATER SOLUBLE COMPOSITIONS COMPRISING PURIFIED CANNABINOIDS [patent_app_type] => utility [patent_app_number] => 17/352032 [patent_app_country] => US [patent_app_date] => 2021-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10535 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17352032 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17140087 [patent_doc_number] => 20210308098 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => WATER SOLUBLE COMPOSITIONS COMPRISING PURIFIED CANNABINOIDS [patent_app_type] => utility [patent_app_number] => 17/352071 [patent_app_country] => US [patent_app_date] => 2021-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10552 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17352071 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19201432 [patent_doc_number] => 20240173331 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-30 [patent_title] => NASAL COMPOSITIONS COMPRISING ALCAFTADINE [patent_app_type] => utility [patent_app_number] => 18/549916 [patent_app_country] => US [patent_app_date] => 2021-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7987 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18549916 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18565631 [patent_doc_number] => 20230255958 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-17 [patent_title] => METHODS OF TREATMENT FOR GASTROINTESTINAL MOTILITY DISORDERS [patent_app_type] => utility [patent_app_number] => 18/001180 [patent_app_country] => US [patent_app_date] => 2021-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20522 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18001180 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18483516 [patent_doc_number] => 20230210813 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE [patent_app_type] => utility [patent_app_number] => 18/001142 [patent_app_country] => US [patent_app_date] => 2021-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10993 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18001142 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17503381 [patent_doc_number] => 20220096483 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => HUMAN PAPILLOMA VIRUS AS PREDICTOR OF CANCER PROGNOSIS [patent_app_type] => utility [patent_app_number] => 17/344777 [patent_app_country] => US [patent_app_date] => 2021-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30261 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17344777 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18522885 [patent_doc_number] => 20230233534 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-27 [patent_title] => SYNTHETIC METHODS FOR PREPARATION OF 4-(2-CHLORO-4-METHOXY-5-METHYLPHENYL)-N-[(1S)-2-CYCLOPROPYL-1-(3-FLUORO-4-METHYLPHENYL)ETHYL]-5-METHYL-N-PROP-2-YNYL-1,3-THIAZOL-2-AMINE [patent_app_type] => utility [patent_app_number] => 18/009662 [patent_app_country] => US [patent_app_date] => 2021-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55672 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -62 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18009662 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17393324 [patent_doc_number] => 11242324 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-08 [patent_title] => Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof [patent_app_type] => utility [patent_app_number] => 17/342923 [patent_app_country] => US [patent_app_date] => 2021-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 26949 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 7 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17342923 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18747057 [patent_doc_number] => 11806347 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-07 [patent_title] => Transmucosal methods for treating psychiatric and neurological conditions [patent_app_type] => utility [patent_app_number] => 17/338573 [patent_app_country] => US [patent_app_date] => 2021-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11218 [patent_no_of_claims] => 58 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17338573 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19430907 [patent_doc_number] => 20240299405 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => APPLICATION OF ATP POTASSIUM CHANNEL MODIFIER IN PREPARATION OF ANTI-DIABETIC NEPHROPATHY DRUG [patent_app_type] => utility [patent_app_number] => 18/013252 [patent_app_country] => US [patent_app_date] => 2021-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6994 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18013252 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18700014 [patent_doc_number] => 11786500 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-17 [patent_title] => Glutaminase inhibitor therapy [patent_app_type] => utility [patent_app_number] => 17/327225 [patent_app_country] => US [patent_app_date] => 2021-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 53 [patent_no_of_words] => 35122 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 388 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17327225 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17496531 [patent_doc_number] => 11285215 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-29 [patent_title] => Pharmaceutical compositions comprising meloxicam [patent_app_type] => utility [patent_app_number] => 17/325616 [patent_app_country] => US [patent_app_date] => 2021-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 33 [patent_no_of_words] => 23781 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 160 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17325616 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17065785 [patent_doc_number] => 20210268000 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => NEFOPAM DOSAGE FORMS AND METHODS OF TREATMENT [patent_app_type] => utility [patent_app_number] => 17/322098 [patent_app_country] => US [patent_app_date] => 2021-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18185 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17322098 [rel_patent_id] =>[rel_patent_doc_number] =>)